Braxia Scientific is making a scientific case for psychedelic medicine

• First mover in the red-hot psychedelic medicine field
• Pioneering the use of psychedelics to treat mental health and addiction disorders
• Strong portfolio of research into psychedelics complements ongoing clinical trials

What Braxia Scientific does:

Braxia Scientific Corp (CSE:BRAX), formerly Champignon Brands Inc (CSE:SHRM) (OTCMKTS:SHRMF) is quickly emerging as a leader in the burgeoning field of psychedelic medicine.

The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders.

As one of the first psychedelic companies to go public, the firm’s network of ketamine clinics complements its sharp focus on research and development.

Its strategic approach establishes a differentiated platform with operating treatment clinics in the US and Canada that also facilitate research and development of a wide range of therapeutic and medical applications of psilocybin, the psychoactive ingredient in mushrooms.

Braxia plans to advance its pursuit of treatments underpinned by psychedelic substances through clinical trials and assembling a compelling IP portfolio, clinical pipeline and drug development platform in the psychedelics space.

It owns 75% of the Canadian Rapid Treatment Centre of Excellence (CRTCE), a fully operational ketamine clinic in Mississauga, Ontario and the only clinic in the country approved by Health Canada to perform psilocybin doses.

Led by CEO Dr Roger McIntyre, a widely recognized expert in the study and treatment of mood disorders, Braxia is blazing a trail in an exciting new industry.

How is it doing:

The big news coming out of the ketamine company was a May 2021 rebrand to Braxia Scientific. The company said the name change reflects its commitment to providing access to and leadership in setting the standard of care for ketamine treatment in depression through its network of clinics as well as its ketamine and psychedelic derivative research and drug development priorities.

Prior to the unveiling, it was a quiet period for the company as it dealt with some regulatory issues in British Columbia in the middle of the year.

In February, CEO Roger McIntyre led an article about the Rapid Mood Screener (RMS) published in Taylor and Francis.com about its ability to differentiate between bipolar disorder and a major depressive disorder (MDD).

The six-item patient-administered RMS differentiates the more cyclical bipolar I disorder compared to MDD in patients with depressive symptoms.

Braxia recently welcomed Olga M Cwiek, a former senior television executive at CBC and CTV, to its board. Cwiek has served as a chairperson of the board of directors and president of Port Hope’s Capitol Theatre For The Performing Arts, which was designated a National Historic Site during her tenure. In other governance roles, Cwiek has served on the board of the Ontario Heart and Stroke Foundation and volunteered as HR adviser to Kid’s Help Phone.

Inflection points:

• Completion of rebranding efforts as Braxia Scientific
• Redesigning its website to facilitate proper access to current information by investors and the wider public
• Rollout of five unique ketamine clinics across Florida, California and the US Eastern Seaboard

What the boss says:

“Our new name – Braxia Scientific – allows us to emphasize our core business objective around changing the way depression and other mental disorders are treated through our growing network of clinics,” said CEO Roger McIntyre.

“Our goal is to improve the access and quality of mental healthcare service to people affected by these disorders in a highly cost-effective manner. Braxia Scientific also aims to develop innovative ketamine and psychedelic drug formulations to provide high impact solutions for the future.”

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Story by ProactiveInvestors